


Singapore production slows in September

After a good run in recent months, a decline in pharmaceuticals production of 11.1%YoY was not the only drag on Singapore's production growth in September. Semiconductor production also fell (the broader electronics category also registered falls), and petrochemicals fell 14.3%YoY worsening a 2.3% fall in August.




Across the board declines spell a downgrade to GDP growth

The breadth of the weakness in September 2018 industrial production is surprising mainly in that it hasn't happened earlier. There have been clear signs of a slowdown in many production sectors in recent months, but until now, there has usually been one sector, or sometimes two, that put in a heroic performance and kept the overall index from slumping on the month.

But not this month. The big change was pharmaceuticals. This has been the clear outperformer this year, but it has finally dipped sharply. With few other sectors picking up the slack (a massive percentage leap in marine engineering is unfortunately too small in absolute terms to overturn the outcome) the result was a disappointing 4.9%MoM decline for a -0.2%YoY growth rate.

Singapore industrial production by major group



Consensus overestimated - now GDP will be revised lower

The consensus estimate for this figure had been a 3.5%YoY increase. Our own forecast was closer to the mark (ING f -1.0%YoY) which derived from the earlier softness of non-oil domestic exports, which provides an unreliable, but in this case accurate lead over the production figures.

Plugging in the new production data into our GDP estimates, we now think that the preliminary 2.6%YoY estimate for 3Q18 GDP will be revised down to 2.4%. Assuming that Singapore grows at a similar pace in 4Q18, we now see full-year growth of 3.3%, consistent with the MAS' forecast of growth for 2018 in the top half of a 2.5% to 3.5% range. However, next year, we anticipate growth slowing to only 2.2% as trade frictions bite.

Author

Robert Carnell

Regional Head of Research, Asia-Pacific

robert.carnell@asia.ing.com

Disclaimer

This publication has been prepared by the Economic and Financial Analysis Division of ING Bank N.V. ("ING") solely for information purposes without regard to any particular user's investment objectives, financial situation, or means. *ING forms part of ING Group (being for this purpose ING Group N.V. and its subsidiary and affiliated companies).* The information in the publication is not an investment recommendation and it is not investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Reasonable care has been taken to ensure that this publication is not untrue or misleading when published, but ING does not represent that it is accurate or complete. ING does not accept any liability for any direct, indirect or consequential loss arising from any use of this publication. Unless otherwise stated, any views, forecasts, or estimates are solely those of the author(s), as of the date of the publication and are subject to change without notice.

The distribution of this publication may be restricted by law or regulation in different jurisdictions and persons into whose possession this publication comes should inform themselves about, and observe, such restrictions.

Copyright and database rights protection exists in this report and it may not be reproduced, distributed or published by any person for any purpose without the prior express consent of ING. All rights are reserved. ING Bank N.V. is authorised by the Dutch Central Bank and supervised by the European Central Bank (ECB), the Dutch Central Bank (DNB) and the Dutch Authority for the Financial Markets (AFM). ING Bank N.V. is incorporated in the Netherlands (Trade Register no. 33031431 Amsterdam). In the United Kingdom

this information is approved and/or communicated by ING Bank N.V., London Branch. ING Bank N.V., London Branch is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. ING Bank N.V., London branch is registered in England (Registration number BR000341) at 8-10 Moorgate, London EC2 6DA. For US Investors: Any person wishing to discuss this report or effect transactions in any security discussed herein should contact ING Financial Markets LLC, which is a member of the NYSE, FINRA and SIPC and part of ING, and which has accepted responsibility for the distribution of this report in the United States under applicable requirements.

Additional information is available on request. For more information about ING Group, please visit <http://www.ing.com>.